Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia

被引:13
作者
Fuehrer, M. [1 ]
机构
[1] Univ Munich, Dr von Haunersches Kinderspital, Dept Haematol Oncol & Bone Marrow Transplantat, D-80337 Munich, Germany
关键词
severe aplastic anaemia in childhood; HSCT in SAA in children; BMT in SAA in children; matched unrelated donor SCT in SAA in children; alternative donor in SAA in children;
D O I
10.1038/bmt.2008.293
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The outcome of haematopoietic SCT (HSCT) from matched unrelated donors in children with severe aplastic anaemia (SAA) has improved significantly in the last decade and should be offered to all children who fail to respond to their first course of combined immunosuppressive therapy. High-resolution typing for HLA class I and II is mandatory for donor selection. In 10/10 or 9/10 alleles matched donors, a non-TBI conditioning based on fludarabine, CY and anti-thymocyte globulin is sufficient to allow for sustained engraftment when unmanipulated BM is used. Owing to increased rates of cGVHD after PBSC transplantation are reported in young patients, BM is the preferred stem cell source. HSCT from mismatched related and unrelated donors are still high-risk procedures. New techniques for graft manipulation such as CD3/CD19 depletion might improve engraftment and immune reconstitution. In T-cell depleted grafts, irradiation-based conditioning seems to be inevitable to reduce the high risk for rejection.
引用
收藏
页码:S97 / S100
页数:4
相关论文
共 25 条
[1]   Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].
Ades, L ;
Mary, JY ;
Robin, M ;
Ferry, C ;
Porcher, R ;
Esperou, H ;
Ribaud, P ;
Devergie, A ;
Traineau, R ;
Gluckman, E ;
Socié, G .
BLOOD, 2004, 103 (07) :2490-2497
[2]   Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia:: a report from the EBMT-SAA Working Party [J].
Bacigalupo, A ;
Locatelli, F ;
Lanino, E ;
Marsh, J ;
Socié, G ;
Maury, S ;
Prete, A ;
Locasciulli, A ;
Cesaro, S ;
Passweg, J .
BONE MARROW TRANSPLANTATION, 2005, 36 (11) :947-950
[3]  
Bagby Grover C, 2007, Hematology Am Soc Hematol Educ Program, P40
[4]   Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia [J].
Benesch, M ;
Urban, C ;
Sykora, KW ;
Schwinger, W ;
Zintl, F ;
Lackner, H ;
Lang, P ;
Handgretinger, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :58-63
[5]   Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion [J].
Bunin, N ;
Aplenc, R ;
Iannone, R ;
Leahey, A ;
Grupp, S ;
Monos, D ;
Pierson, G .
BONE MARROW TRANSPLANTATION, 2005, 35 (04) :369-373
[6]   A fludarabine-based conditioning regimen for severe aplastic anemia [J].
Chan, KW ;
Li, CK ;
Worth, LL ;
Chik, KW ;
Jeha, S ;
Shing, MK ;
Yuen, PM .
BONE MARROW TRANSPLANTATION, 2001, 27 (02) :125-128
[7]  
Deeg H J, 1999, Biol Blood Marrow Transplant, V5, P243, DOI 10.1053/bbmt.1999.v5.pm10465104
[8]   Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation [J].
Deeg, HJ ;
Amylon, MD ;
Harris, RE ;
Collins, R ;
Beatty, PG ;
Feig, S ;
Ramsay, N ;
Territo, M ;
Khan, SP ;
Pamphilon, D ;
Leis, JF ;
Burdach, S ;
Anasetti, C ;
Hackman, R ;
Storer, B ;
Mueller, B .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) :208-215
[9]  
Eapen M, 2000, BRIT J HAEMATOL, V111, P754
[10]   Immunosuppressive therapy for aplastic anemia in children:: a more severe disease predicts better survival [J].
Führer, M ;
Rampf, U ;
Baumann, I ;
Faldum, A ;
Niemeyer, C ;
Janka-Schaub, G ;
Friedrich, W ;
Ebell, W ;
Borkhardt, A ;
Bender-Goetze, C .
BLOOD, 2005, 106 (06) :2102-2104